Clinical trials: Immune-related Adverse Events
Drug/Agent Toxicity by Tissue/Organ, Leukemia
05-001: Treatment of Acute Lymphoblastic Leukemia in Children
RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis.
- Trial name
- NCT00400946
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- 8 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Dana-Farber Cancer Institute
Immune-related Adverse Events, Advanced Solid Tumor
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
The purpose of this study is to examine how effective rituximab or tocilizumab are in treating side effects for people who are receiving immunotherapy treatment requiring prolonged steroid use.
- Trial name
- NCT04375228
- Testing
- Rituximab, Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Asthma, Aspirin-Induced
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
The purpose of this phase 2 study is to assess the safety and efficacy of oral ifetroban for the treatment of aspirin-exacerbated respiratory disease (AERD).
- Trial name
- NCT03028350
- Testing
- Ifetroban Oral Capsule
- Where
- 16 sites in United States
- Volunteers
- 54 people
- Sponsor
- Cumberland Pharmaceuticals
Acute Liver Failure, Acute Liver Injury
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute liver failure/acute liver injury (ALF/ALI) in regard to: safety and tolerability; metabolism of the compound to glutamine and…
- Trial name
- STOP-ALF (NCT01548690)
- Testing
- Ornithine Phenylacetate
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- William Lee
Cardiotoxicity, Breast Cancer
PROactive Evaluation of Function to Avoid CardioToxicity
This study is intended to evaluate the ability of an intramyocardial strain analysis package with cardiac MRI to assist in the early detection and management of cardiotoxicity from therapeutics used to treat cancer.
- Conditions
- Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma
- Trial name
- PROACT (NCT03862131)
- Testing
- MyoStrain®
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Asthma, Aspirin-Induced, Aspirin Exacerbated Asthma
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
The investigators are doing this research study to find out if giving a drug called prasugrel, which is used to prevent blood clots, can reduce reactions to aspirin in people with aspirin exacerbated respiratory disease (AERD)…
- Trial name
- Aspirin (NCT01597375)
- Testing
- Prasugrel Oral Tablet
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Elliot Israel, MD
Systemic Lupus Erythematosus
A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
The purpose of this study is to compare the genotype-based personal prescription of cyclophosphamide with the traditional prescription.
- Trial name
- SLE (NCT01689350)
- Testing
- Genotype Detection
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Breast Cancer, Non-Hodgkin's Lymphoma
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
The purpose of this study is to determine whether the drug mesna is able to block a series of chemical changes that occur in the blood of patients who receive the chemotherapy medicine doxorubicin.
- Trial name
- NCT01205503
- Testing
- Mesna, Saline, Doxorubicin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mara Chambers
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Chemical Injuries, Unspecified Complication of Corneal Transplant
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
The purpose of the pilot study is to test the efficacy and safety of riboflavin/Ultraviolet A (UVA) cross-linked human donor corneas as carriers for the Boston Keratoprosthesis (Boston KPro) in patients with higher risk for…
- Conditions
- Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid
- Trial name
- NCT01582880
- Testing
- Riboflavin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph B. Ciolino, MD
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
The goal of this study is to evaluate the effect of tofacitinib in patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The primary outcome of the study is the time to complete re-epithelialization.
- Trial name
- NCT06474078
- Testing
- Tofacitinib
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Chang Gung Memorial Hospital
Allergy Drug, Allergic Reaction
Preoperative Survey to Evaluate Patient Allergy
The study will only involve identification of the listed allergies from the electronic medical record and investigation into the symptoms that prompted this allergy listing.
- Conditions
- Allergy Drug, Allergic Reaction, Pediatric, Surgery
- Trial name
- NCT05670756
- Testing
- Survey
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Nationwide Children's Hospital
Advanced Malignant Solid Neoplasm
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
This phase I/II trial investigates the side effects and how well CD24Fc works in treating immune related adverse events in patients with solid tumors that have spread to other places in the body (advanced).
- Trial name
- NCT04552704
- Testing
- CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Tianhong Li
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
- Conditions
- Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT04313725
- Testing
- Tangible Boost
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Tangible Science
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Asthma, Aspirin-Induced, Chronic Rhinosinusitis With Nasal Polyps
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
Primary objective: to investigate the efficacy of Mepolizumab 100 milligram (mg) every month compared to placebo in reducing validated Sinonasal Outcome Test -22 score and on reducing endoscopic Nasal Polyp Score.
- Trial name
- AirGOs-biol (NCT04823585)
- Testing
- Mepolizumab
- Where
- Finland
- Volunteers
- 95 people
- Sponsor
- Helsinki University Central Hospital
Asthma, Aspirin-induced
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
To diagnose aspirin hypersensitivity in asthmatics by using and safe, low-dose aspirin oral challenge. Hypothesis 1: A low dose of oral ASA (20 or 40 mg) will induce significantly different concentrations of arachidonic acid…
- Trial name
- ASAS (NCT01320072)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Montefiore Medical Center
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal…
- Trial name
- NCT02037347
- Testing
- Palifermin
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brett King